

## INFORMATION DISCLOSURE STATEMENT

Applicate

Goddard et al. (as amended herein)

App. No

10/063,728

Filed

May 8, 2002

For

A NUCLEIC ACID

UNDEREXPRESSED IN STOMACH

TUMOR (as amended herein)

Examiner

Seharaseyon, J.

Art Unit

1647

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 28 references to be considered by the Examiner. Also enclosed are 14 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

05/12/2005 NNGUYEN1 00000033 10063728

04 FC:1806

180.00 OP

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record

Customer No. 30,313

(619) 235-8550

1695828\050505

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/063,728

Filing Date May 8, 2002

First Named Inventor Goddard et al. (as amended)

Art Unit 1647

Examiner Seharaseyon, J.

Attorney Docket No. GNE.3230R1C157

Multiple sheets used when necessary)

SHEET 1 OF 2

U.S. PATENT DOCUMENTS								
Examiner Initials PAI	C. C.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear			
	1	5,965,397	10-12-1999	Jacobs et al.				
	2	6,025,156	02-15-2000	Gwynn, et al.				
	3	6,124,433	09-26-2000	Falb, et al.				
	4	6,156,500	12-05-2000	Falb, Dean				
0	5	6,162,604	12-19-2000	Jacob, Chaim O.				
	6	6,228,582	05-08-2001	Rodier, et al.				
	7	6,395,306	05-28-2002	Cui, et al.				
	8	6,414,117	07-02-2002	Levinson, D. A.				
	9	6,465,185	10-15-2002	Goldfine, et al.				
	10	6,498,235	12-24-2002	Sheppard, et al.				
7	11	6,562,343	05-13-2003	Levinson, D. A.				
	12	6,645,499	11-11-2003	Lal, et al.				
	13	6,730,502	05-04-2004	Van Hijum, et al.				
	14	6,737,522	05-18-2004	Sundick, et al.				

NON PATENT LITERATURE DOCUMENTS						
Examiner Ci Initials No		itom (had) magazina inumal agrid aumagaium agtalag ata \ data ====/a\ iidiii				
	15	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 403-404, 453. New York: Garland Publishing.				
	16	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.				
	17	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.				
	18	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. Molecular and Cellular Biology, 1720-1730.				
	19	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .				
	20	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns.  Cancer Research, 62:6240-6245.				
	21	LEWIN, B. 1994. Oncogenes: Gene Expression and Cancer, Chap. 39, pp.1196-1201. Genes V. New York: Oxford University Press.				

**Date Considered** 

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

	Application No.	10/063,728
INFORMATION DISCLOSURE	Filing Date	May 8, 2002
STATEMENT BY APPLICANT	First Named Inventor	Goddard et al. (as amended)
	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	Seharaseyon, J.

Attorney Docket No.

GNE.3230R1C157

SHEET 2 OF 2

MAL			
12		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	PHO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	22	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	23	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	·
	24	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	25	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular &amp; Cellular Proteomics</i> , 1:37-45.	
	26	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	27	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol. Annu, 1(27):165-190.	
	28	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World Journal of Surgical Oncology, 2:13.	

1695902\050505

Examiner Signature

**Date Considered** 

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.